GlassScriptPhysician profile
Dylan L Juda
NPI 1407452709
$3,435.07
in general payments reported to CMS, 2019-2025
22 companies · $590 in 2025
The $590 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $750 · 2023: $1,140 · 2024: $719 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.23 |
| Education | $165.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $578.85 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $429.03 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.84 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $290.74 | 2022-2025 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $276.85 | 2021-2025 | Lupkynis |
| Amgen INC. | $209.71 | 2022-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $196.60 | 2022-2024 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $183.59 | 2023-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $159.23 | 2024-2025 | |
| Medtronic, INC. | $140.11 | 2021-2024 | Minimed 780g |
| Ardelyx, INC. | $121.60 | 2023-2025 | Ibsrela |
| Vifor Pharma, INC. | $117.71 | 2021-2024 | Veltassa |
| Travere Therapeutics, INC. | $83.06 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $70.91 | 2021-2025 | Jynarque |
| Horizon Therapeutics Plc | $58.20 | 2021-2023 | Krystexxa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $46.75 | 2022-2025 | Ozempic |
| Abbott Laboratories | $44.13 | 2025 | Freestyle Libre 3, Architect |
| Ani Pharmaceuticals, INC. | $40.56 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.56 | 2025 | |
| Baxter Healthcare | $20.64 | 2023 | Renal - Pd |
| Scpharmaceuticals INC. | $18.31 | 2024 | |
| Fresenius USA Marketing, INC. | $16.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Juda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.